Herbs (Global Traditional) · Amazonian
Psychotria viridis
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Psychotria viridis is an Amazonian plant containing N,N-dimethyltryptamine (DMT) and other tryptamine alkaloids that exhibit neuroprotective and anti-tumor properties. Research shows its extracts provide over 90% acetylcholinesterase inhibition and selective cytotoxicity against cancer cells.
Psychotria viridis, commonly known as chacruna, is a shrubby plant native to the Amazon region belonging to the Rubiaceae family. The plant serves as the primary source of N,N-dimethyltryptamine (DMT) in traditional ayahuasca brew, with its leaves extracted through decoction or infusion methods combined with Banisteriopsis caapi.
Clinical research on isolated Psychotria viridis is extremely limited, with no human RCTs or meta-analyses identified. A 2015 rat study (PMID: 26049017) examined ayahuasca infusion containing P. viridis, showing antidepressant-like effects and serotoninergic activation with transient neurotoxicity. Most human research focuses on ayahuasca brews rather than P. viridis alone.
No clinically studied dosage ranges for P. viridis extracts, powders, or standardized forms have been identified in human trials. Traditional use involves preparation as part of ayahuasca brew, but specific P. viridis dosing is not standardized. Consult a healthcare provider before starting any new supplement.
Psychotria viridis (Chacruna) is not consumed as a food/nutritional source and lacks a standard nutritional profile in terms of macronutrients. Its significance is entirely phytochemical/ethnobotanical. Key bioactive compounds include: **Tryptamine alkaloids:** • N,N-Dimethyltryptamine (DMT) — approximately 0.1–0.61% dry leaf weight (mean ~0.3% w/w); the primary psychoactive constituent, a potent serotonin 5-HT2A receptor agonist and sigma-1 receptor agonist. Oral bioavailability is negligible without co-administration of a monoamine oxidase inhibitor (e.g., β-carboline alkaloids from Banisteriopsis caapi). • N-Methyltryptamine (NMT) — trace to ~0.04% dry weight, minor tryptamine alkaloid. • 2-Methyl-1,2,3,4-tetrahydro-β-carboline (trace amounts reported). **Phenolic and polyphenolic compounds:** • Total phenolic content reported at approximately 45–85 mg gallic acid equivalents (GAE)/g dry extract (varies by solvent fraction). • Flavonoids including quercetin and kaempferol glycosides detected in methanolic and ethyl acetate fractions. • Proanthocyanidins and tannins present in moderate concentrations. **Terpenoids and other compounds:** • Ursolic acid and oleanolic acid (pentacyclic triterpenes) detected in chloroform fractions. • β-Sitosterol and stigmasterol (phytosterols) identified in non-polar fractions. • Essential oil fraction contains linalool and minor monoterpenes (trace). **Minerals (leaf tissue, approximate):** Limited analytical data; general tropical leaf estimates suggest presence of potassium (10–25 mg/g dry weight), calcium (8–20 mg/g), magnesium (2–5 mg/g), iron (0.05–0.2 mg/g), and manganese (0.02–0.1 mg/g), though species-specific mineral profiling is sparse. **Vitamins:** No reliable quantitative data on vitamin content specific to P. viridis. **Fiber/Protein:** Leaves contain typical tropical-leaf-range crude protein (~8–15% dry weight) and crude fiber (~15–25% dry weight), but these values are estimated from related Rubiaceae species and are not nutritionally relevant given the plant is not eaten as food. **Bioavailability notes:** DMT is rapidly metabolized by monoamine oxidase-A (MAO-A) in the gut and liver, rendering it orally inactive unless combined with MAO inhibitors (as in ayahuasca preparations). Phenolic compounds likely have moderate bioavailability typical of plant polyphenols (5–10% absorption). The acetylcholinesterase-inhibiting activity is concentrated in chloroform and ethyl acetate fractions (>90% inhibition in vitro), suggesting lipophilic/mid-polarity alkaloids and terpenoids as active agents, though in-vivo bioavailability of these fractions remains uncharacterized.
Psychotria viridis contains DMT and related tryptamine alkaloids that inhibit acetylcholinesterase enzyme activity, potentially enhancing cholinergic neurotransmission. The plant's compounds also demonstrate selective cytotoxic mechanisms against B16F10 melanoma and 4T1 breast cancer cell lines while sparing normal cellular function. Additionally, tryptamine derivatives may modulate serotonergic pathways contributing to potential mood-regulating effects.
Current evidence for Psychotria viridis comes exclusively from preliminary in-vitro laboratory studies. Chloroform and ethyl acetate extracts demonstrated greater than 90% acetylcholinesterase inhibition in enzyme assays. Anti-cancer research showed selective cytotoxicity against B16F10 and 4T1 cancer cell lines without damaging normal cells. No human clinical trials or animal studies have been conducted to validate these preliminary findings or establish therapeutic dosing protocols.
Psychotria viridis contains psychoactive DMT and should be considered potentially dangerous when consumed. The plant may interact with MAO inhibitors, potentially causing dangerous serotonin syndrome or prolonged psychoactive effects. No safety data exists for pregnant or breastfeeding women, and use should be avoided. Legal restrictions apply in most countries due to DMT content, and consumption may cause psychological distress, anxiety, or adverse psychiatric reactions.
